CDC Issues Travel Alert as Dengue Cases Surge Worldwide

The Centers for Disease Control and Prevention has issued an elevated travel alert for dengue fever as global case numbers remain exceptionally high, with particular concern for popular vacation destinations in the Americas, Asia, and the Pacific.

Global Dengue Burden Reaches Persistent Highs

Publicly available surveillance data indicate that dengue remains at historically high levels worldwide, following record-breaking outbreaks in 2024 and sustained transmission into 2025. Regional summaries from international health agencies describe tens of millions of suspected and confirmed infections across more than 100 countries, underscoring that dengue is now among the most widespread mosquito-borne viral diseases globally.

Reports from the Americas highlight the scale of the problem. Regional health bulletins show that 2024 brought the highest number of dengue cases on record for the hemisphere, with Brazil, Colombia, Peru, Argentina, and several Caribbean territories among the hardest hit. While early analyses for 2025 suggest some easing of transmission in parts of the region, case totals remain well above long-term averages, keeping health systems under ongoing pressure.

Global situation updates from specialized European monitoring centers also note that dengue has continued to spread across tropical and subtropical zones in Asia and the Western Pacific, with large outbreaks in countries such as Bangladesh, India, Thailand, and the Philippines. Warmer temperatures, intense rainfall events, rapid urbanization, and the expansion of Aedes mosquitoes are all identified as factors shaping the current pattern of transmission.

International briefings further indicate that dengue has become a recurring seasonal concern in some parts of Africa and the Eastern Mediterranean, although the overall burden there remains lower than in the Americas and Southeast Asia. Even so, more frequent introductions by travelers and climate-sensitive changes in mosquito distribution are prompting closer monitoring in these regions.

CDC Travel Alert Targets High-Risk Destinations

The CDC has responded to these trends by issuing an elevated Travel Health Notice for dengue, categorized as an Alert (Level 2). This level advises travelers to practice enhanced precautions if visiting areas with frequent or continuous transmission. The alert emphasizes that dengue risk is not limited to remote or rural locations but includes many major cities and resort areas favored by international tourists.

According to CDC travel health resources, areas with frequent or continuous dengue risk presently include large parts of Latin America and the Caribbean, wide swaths of South and Southeast Asia, and numerous islands in the tropical Pacific and Indian Oceans. Examples include Mexico, much of Central America, and countries such as Brazil, Peru, and Colombia, as well as Puerto Rico and other Caribbean islands. In Asia, heavily visited destinations like India, Thailand, Vietnam, the Philippines, Indonesia, Malaysia, and Singapore are all listed among locations with established dengue transmission.

CDC technical guidance notes that travelers to these destinations may be exposed to dengue both in urban centers and in smaller communities where Aedes aegypti and Aedes albopictus mosquitoes thrive. Risk is often highest during and immediately after the rainy season, when standing water allows mosquito populations to surge. However, in many tropical cities transmission can continue year-round, making seasonally timed travel less protective than it might be for other vector-borne diseases.

For cruise passengers and island-hopping travelers, CDC travel pages point out that dengue is endemic in several popular archipelagos, including parts of the Caribbean, Pacific territories such as American Samoa and Fiji, and Indian Ocean destinations like the Maldives and Réunion. Because ships may call at multiple affected ports in a short period, travelers are encouraged to maintain consistent mosquito precautions from one stop to the next.

Americas and U.S. Territories Remain a Focus of Concern

In the Western Hemisphere, recent epidemiological updates from regional bodies show that dengue continues to circulate widely in Latin America and the Caribbean following the unprecedented surge in 2024. Brazil has reported several million cases across consecutive seasons, while neighboring countries including Argentina, Paraguay, Bolivia, Peru, and Colombia have all documented substantial outbreaks in recent years.

U.S. territories and nearby island jurisdictions feature prominently in current travel advisories. Information posted by the CDC highlights that Puerto Rico has experienced sustained above-threshold dengue activity since early 2024, with continued elevated case numbers into 2025. Other Caribbean locations, such as the Dominican Republic and several smaller island territories, have also reported high incidence, reflecting how closely tourism hubs overlap with zones of intense transmission.

Within the continental United States, dengue is not considered endemic nationwide, but clusters of locally acquired infections have occurred in recent seasons in Florida, Texas, and California. CDC health alerts issued in 2024 noted that these local cases were linked to introductions from travelers and subsequent spread in neighborhoods where Aedes mosquitoes are established. While the absolute numbers remain small compared with Latin America, the pattern illustrates how quickly imported infections can seed limited outbreaks.

Travel-related case counts provide an additional window into risk. CDC summaries and state-level arbovirus surveillance reports from 2024 and early 2025 document more than a thousand dengue infections diagnosed in returning travelers in states such as Florida, California, and New York alone. Many of these individuals had recently visited Mexico, Central America, South America, or the Caribbean, reinforcing the advisory message that even short trips can lead to infection.

Rising Travel-Linked Cases in Europe and Beyond

European surveillance agencies are also tracking a marked increase in dengue among travelers, along with limited local spread in areas where competent mosquitoes are present. Data compiled by the European Centre for Disease Prevention and Control show that travel-associated dengue cases reported by EU and European Economic Area countries reached new highs in 2023 and 2024, paralleling the large outbreaks in the Americas and Asia.

In addition, ECDC situation reports describe a growing number of locally acquired dengue infections within parts of southern Europe over the past several summers, particularly in France and Italy, where Aedes albopictus has become firmly established. One recent communication highlighted more than 300 locally acquired dengue cases recorded across Europe in 2024, a sharp increase compared with previous years. For 2025, early-season updates indicate that authorities are maintaining heightened mosquito surveillance and case detection, even as reported autochthonous infections have so far remained limited.

International travel patterns have direct implications for these European trends. Many of the countries reporting higher numbers of travel-linked infections have strong air connections with Latin America, the Caribbean, and Southeast Asia, where dengue is endemic. Public health analyses note that viremic travelers returning from these regions can introduce the virus into European communities that now support seasonal Aedes mosquito populations, opening the door to local transmission during the warm months.

Beyond Europe, health ministries in regions such as the Middle East and North Africa have flagged sporadic dengue activity in countries where Aedes mosquitoes are expanding. While the number of affected travelers is smaller than in the Americas or Asia, the pattern further supports the CDC’s decision to frame dengue as a global travel health concern rather than a risk confined to a limited set of destinations.

What the Alert Means for Travelers

The CDC’s Level 2 alert does not advise canceling trips, but it does urge travelers to treat dengue as a significant health consideration, especially when planning visits to tropical or subtropical regions. Guidance documents stress that there is no widely available vaccine or specific antiviral treatment for most travelers, so prevention depends primarily on avoiding mosquito bites and recognizing symptoms early.

For individuals headed to areas with frequent dengue transmission, CDC travel health materials recommend using Environmental Protection Agency–registered insect repellents, wearing long sleeves and long pants when practical, and choosing accommodations with air conditioning or well-fitted window and door screens. Travelers are also encouraged to reduce mosquito breeding opportunities around lodgings by noting and avoiding standing water in containers, plant pots, or outdoor areas where mosquitoes could lay eggs.

Publicly available clinical guidance indicates that anyone developing fever, severe headache, eye pain, muscle and joint aches, rash, or unusual bruising during or after travel to an affected area should seek prompt medical assessment and mention possible dengue exposure. Early diagnosis allows for closer monitoring of warning signs and supportive care that can reduce the risk of complications. Health agencies further advise travelers to avoid self-medicating with nonsteroidal anti-inflammatory drugs until dengue has been ruled out, due to concerns about bleeding.

For the travel industry, the ongoing dengue situation presents a complex challenge. Airlines, cruise operators, and tour companies are monitoring advisories while emphasizing that informed travelers who follow bite-prevention measures can continue to visit affected destinations. As the CDC refines its notices and global surveillance evolves, prospective travelers are being urged to review the latest country-specific information shortly before departure and to plan itineraries with the changing geography of dengue firmly in mind.